Page 59 - Medication Guide News Today

frontMIND Study Evaluating Tafasitamab Combination as a  First-line Treatment for Diffuse Large B-Cell Lymphoma PLANEGG/MUNICH, Germany and WILMINGTON, Del., USA - May 11, 2021 - MorphoSys AG (FSE:MOR; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) compared to R-CHOP alone as firs...

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma ACCESSWIRE 12 May 2021, 06:05 GMT+10 PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal Phase 3 frontMIND study evaluating tafasitamab and lenalidomide in addition to rituxima...

MorphoSys AG: MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma The frontMIND (NCT04824092) trial is a randomized, double-blind, placebo-controlled, global Phase 3 clinical study in previously untreated high-intermediate and high-risk DLBCL patients that is conducted in partnership with the German Lymphoma Association (GLA), the Italian Lymphoma study group and the US Oncol...

Applications Based on Progression-Free Survival, Overall Survival, and Objective Response Rate Data From Respective Pivotal Phase 3 Trials Merck known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration has accepted and granted priority review for applications seeking two new approvals for the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, … Applications Based on Progression-Free Survival, Overall Survival, and Objecti...

Merck Highlights Scientific Data at 2021 ASCO Annual Meeting Across More Than 20 Cancer Types From Broad Oncology Research Program First-Time Data for KEYTRUDA ® in Early-Stage Kidney Cancer and for LYNPARZA ® in Early-Stage Breast Cancer To Be Featured in ASCO Plenary Session New Data To Be Presented for KEYTRUDA in Advanced Gastric Cancer Merck known as MSD outside the United States and Canada, today announced that data spanning more than 20 cancer types from its oncology research program w...

How I Helped My Son Through His Treatment-Resistant Depression Diagnosis Allison © The Mighty young asian couple staying at home My name is Allison, and I’m a mother to five children, including two stepchildren. My son Austin is 21 years old, in the middle of my five kids, and lives with treatment-resistant depression (TRD). He loves to cook, garden and compost and is planning to go to chef school, once the coronavirus calms down.  Austin’s always been a skilled learner,...

5 - * Adjusted (Adj.) basis excludes the impact of exceptional items as referenced in Notes 3 and 4. Comment by Mark Crossley, CEO of Indivior PLC "We have seen an encouraging start in FY 2021 with growth in net revenue, operating profit and cash from execution against our strategic priorities. Despite the ongoing impacts of COVID-19, SUBLOCADE® (buprenorphine extended-release) injection achieved solid net revenue growth both on a sequen...

  Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq ® (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express high levels of PD-L1 (PD-L1–stained tumor-...

(2) Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (mUC, bladder cancer) who are not eligible for cisplatin-containing chemotherapy and whose tumors express high levels of PD-L1 (PD-L1-stained tumor-infi...

Share this article Share this article INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Companys (NYSE: LLY) Taltz ® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin...